Remdesivir Efficacy in Coronavirus Disease

Remdesivir in COVID-19 Treatment: A Randomised Trial

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04345419

Enrollment

200

Registered

2020-04-14

Start date

2020-06-16

Completion date

2020-12-01

Last updated

2021-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID

Brief summary

COVID 19 treatment using Remedesvir.

Detailed description

COVID 19 treatment using Remedesvir. Is this drug effective?

Interventions

DRUGRemdesivir

Remdesivir as antiviral drug

OTHERStandard of care treatment

Standard of care treatment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* COVID 19 patients

Exclusion criteria

* allergy or contraindication to the drug

Design outcomes

Primary

Measure	Time frame	Description
Number of patients with improvement or mortality	6 months	the estimated number of patients with improvement or mortality

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026